Posted by Michael Wonder on 23 Feb 2022
PHARMAC’s clinical experts recommend funding Trikafta
23 February 2022 - PHARMAC today announces its clinical advisory committee PTAC has recommended funding cystic fibrosis treatment Trikafta with medium priority for over 12s.
“Our Pharmacology and Therapeutics Advisory Committee (PTAC) has recommended, with medium priority, that Pharmac fund Trikafta for those over the age of 12,” says Pharmac’s Director of Operations Lisa Williams. “PTAC are waiting to make a recommendation about funding for people aged between six and 11 until further evidence has been provided.”
